Clearmind (CMND) 6-K: MEAI IP update; filings incorporated

Rhea-AI Filing Summary

Clearmind Medicine (CMND) furnished a Form 6-K announcing a press release titled “Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing.”

The filing also states that the first four paragraphs of the press release are incorporated by reference into the company’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695) as of November 5, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind Medicine (CMND) file?

Clearmind furnished a Form 6-K that includes a press release about expanding global IP protection for MEAI via a new South Korea patent filing.

What content from the press release is incorporated by reference?

The first four paragraphs of the press release are incorporated by reference into Clearmind’s registration statements.

Which registration statements are affected for CMND?

Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).

What is the subject of the incorporated press release?

It addresses global IP protection for MEAI in depression treatment, noting a new South Korea patent filing.

When was the press release issued?

The press release was issued on November 5, 2025.

Does the 6-K mention financial results or transactions?

No. The filing highlights the press release and its incorporation by reference into existing registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 04:01 PM EST Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on November 5, 2025, titled “Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing”.

The first four paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: November 5, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3